Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Zolgensma’s impressive early sales figures spur hopes that gene therapy could finally be coming of age.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.